What is King Pharmaceuticals's derivative assets?

King Pharmaceuticals (KG) reported derivative assets of $3.98M in Q1 2026.

What does derivative assets mean?

Fair value of derivative contracts (swaps, options, forwards, futures) in a net gain position — represents amounts owed to the firm by counterparties.

King Pharmaceuticals KG Derivative assets

Derivative assets at other companies

SiriusPointSPNT

$40.6M+566%

Skyward Specialty Insurance Group, Inc.SKWD

$188.19M—

Kearny FinancialKRNY

$8.6M-63.2%

Community Financial SystemCBU

$5.42M—

Arch Capital GroupACGL

——

Reinsurance Group of AmericaRGA

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilities.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's derivative assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's derivative assets?: King Pharmaceuticals (KG) reported derivative assets of $3.98M in Q1 2026.
What does derivative assets mean?: Fair value of derivative contracts (swaps, options, forwards, futures) in a net gain position — represents amounts owed to the firm by counterparties.